Sign In
Buy ELVN
$36.03
+0.510 (+1.44%)
At Close: Jun 03, 2026
Imara Changes Primary Endpoint In Mid-Stage Sickle Cell Disease Trial
10:36am, Monday, 22'nd Nov 2021
Imara Inc (NASDAQ: IMRA) has announced a change to the primary endpoint for the Ardent Phase 2 trial of tovinontrine (IMR-687) in sickle cell disease. Imara is a biopharmaceutical company focused o
7 Penny Stocks to Book Profits on Before 2022
02:30pm, Tuesday, 16'th Nov 2021
Penny stocks can turn a quick profit. These 7 picks are designed to do so before the end of this year and cover multiple sectors.
IMARA Inc. (IMRA) CEO Rahul Ballal on Q3 2021 Results - Earnings Call Transcript
04:48pm, Tuesday, 09'th Nov 2021
IMARA Inc. (IMRA) CEO Rahul Ballal on Q3 2021 Results - Earnings Call Transcript
Imara to Present Clinical and Preclinical Data at the American Society of Hematology (ASH) Annual Meeting 2021
09:17am, Thursday, 04'th Nov 2021
Tovinontrine (IMR-687) VOC data in patients with sickle cell disease from ongoing Phase 2a open-label extension study and preclinical models of beta-thalassemia to be presented
Imara to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 15'th Sep 2021
SVB Leerink CybeRx Series and 2021 Cantor Virtual Global Healthcare Conference SVB Leerink CybeRx Series and 2021 Cantor Virtual Global Healthcare Conference
Imara to Present at Upcoming Investor Conferences
07:00am, Friday, 03'rd Sep 2021
Citi 16th Annual BioPharma Virtual Conference, H.C. Wainwright 23rd Annual Global Investment Conference and Morgan Stanley 19th Annual Global Healthcare Conference Citi 16th Annual BioPharma Virtual C
IMARA's (IMRA) CEO Rahul Ballal on Q2 2021 Results - Earnings Call Transcript
02:44pm, Sunday, 08'th Aug 2021
IMARA's (IMRA) CEO Rahul Ballal on Q2 2021 Results - Earnings Call Transcript
Imara Reports Second Quarter 2021 Financial Results and Business Highlights
07:00am, Friday, 06'th Aug 2021
Accelerated enrollment in Phase 2b trials in sickle cell disease and beta-thalassemia; interim analyses expected in fourth quarter of 2021
Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sickle Cell Disease
07:15am, Thursday, 05'th Aug 2021
Interim analysis expected in fourth quarter of 2021 and primary endpoint readout now expected in first quarter of 2022 Interim analysis expected in fourth quarter of 2021 and primary endpoint readout
Imara to Webcast Conference Call of Second Quarter 2021 Financial Results and Business Highlights
07:00am, Friday, 30'th Jul 2021
BOSTON, July 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients sufferi
Imara Announces Pricing of Public Offering
10:58pm, Tuesday, 13'th Jul 2021
BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to tr
Biotech Losers In 2021 That Could Bounce Big In The Second Half
05:02pm, Saturday, 03'rd Jul 2021
Biotech stocks are tricky investment bets that require careful analysis and scrutiny. A stock that has fallen off a cliff in reaction to a binary event can neither be written off entirely nor picked a
Imara Announces Recipients of the Second Annual Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders
07:00am, Thursday, 17'th Jun 2021
Imara has continued and expanded the program to award 30 grants totaling $150,000 to fund nonprofit, community-based organizations supporting individuals with sickle cell disease and beta-thalassemia
Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
03:00am, Friday, 11'th Jun 2021
Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687
2 Falling Knives to Catch
11:36am, Friday, 04'th Jun 2021
Unexpectedly, Wall Street recommends acquiring shares of Protara Therapeutics Inc ( TARA , Financial) and IMARA Inc ( IMRA , Financial), despite the fact that these two equities have shown poor perfor
